Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
MBRX 
Moleculin Biotech Inc (MBRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: MBRX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $7
1 Year Target Price $7
| 0 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -69.46% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 19.57M USD | Price to earnings Ratio - | 1Y Target Price 7 |
Price to earnings Ratio - | 1Y Target Price 7 | ||
Volume (30-day avg) 3 | Beta 1.4 | 52 Weeks Range 0.25 - 3.33 | Updated Date 08/15/2025 |
52 Weeks Range 0.25 - 3.33 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.74 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -67.42% | Return on Equity (TTM) -503.8% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 12431414 | Price to Sales(TTM) - |
Enterprise Value 12431414 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.52 | Shares Outstanding 30207500 | Shares Floating 29234027 |
Shares Outstanding 30207500 | Shares Floating 29234027 | ||
Percent Insiders 3.52 | Percent Institutions 5.52 |
Upturn AI SWOT
Moleculin Biotech Inc
Company Overview
History and Background
Moleculin Biotech, Inc. was founded in 2003. It is a clinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, and has evolved from a research-based company to one focused on clinical trials. A significant milestone includes the advancement of Annamycin into clinical trials.
Core Business Areas
- Drug Development: Focuses on developing drug candidates for cancer treatment, particularly those addressing unmet medical needs.
Leadership and Structure
The leadership team includes Walter Klemp as Chairman and CEO. The company operates with a management team overseeing research, clinical development, and business operations.
Top Products and Market Share
Key Offerings
- Annamycin: An intercalating anthracycline designed to avoid multidrug resistance mechanisms. It is in clinical development for relapsed or refractory acute myeloid leukemia (AML). Market share data is currently unavailable as the product is not yet approved. Competitors include existing AML therapies such as chemotherapy regimens and targeted therapies from companies like Pfizer, Novartis, and AbbVie.
- WP1066: An STAT3 inhibitor targeting solid tumors and hematological malignancies. Market share data is currently unavailable as the product is in pre-clinical and clinical trials. Competitors include other STAT3 inhibitors in development and existing cancer therapies.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and regulated, requiring significant investment in research and development. The oncology segment is a major area of focus with high growth potential due to the increasing prevalence of cancer and advancements in treatment options.
Positioning
Moleculin Biotech is positioned as a clinical-stage company with a focus on novel cancer therapies. Its competitive advantage lies in its unique drug candidates that target specific cancer mechanisms.
Total Addressable Market (TAM)
The total addressable market for cancer therapies is estimated at hundreds of billions of dollars annually. Moleculin is targeting specific segments within this market, such as AML and solid tumors, positioning them to capture a portion of the TAM if their drug candidates are approved.
Upturn SWOT Analysis
Strengths
- Novel drug candidates with unique mechanisms of action
- Experienced management team
- Focus on unmet medical needs in oncology
Weaknesses
- Limited financial resources
- High dependence on successful clinical trials
- No currently approved products
Opportunities
- Positive clinical trial results could lead to partnerships and funding
- Potential for orphan drug designation and accelerated approval pathways
- Expanding pipeline with new drug candidates
Threats
- Failure of clinical trials
- Competition from larger pharmaceutical companies
- Regulatory hurdles and delays
Competitors and Market Share
Key Competitors
- PFE
- NVS
- ABBV
Competitive Landscape
Moleculin Biotech faces significant competition from larger pharmaceutical companies with greater resources. Its advantages lie in its novel drug candidates and focus on specific cancer targets. However, its lack of approved products and limited funding pose challenges.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data is not provided in the question. Cannot fulfill requirement.
Future Projections: Future projection data is not provided in the question. Cannot fulfill requirement.
Recent Initiatives: Recent initiatives include advancing Annamycin into later-stage clinical trials and expanding the pipeline with new drug candidates.
Summary
Moleculin Biotech is a clinical-stage pharmaceutical company developing novel cancer therapies. It's focusing on AML and solid tumors with Annamycin and WP1066. While it has promising drug candidates, the company faces challenges related to funding and competition from larger players. Positive clinical trial results are essential for its future success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Investment decisions should be based on thorough research and consultation with a financial professional.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Moleculin Biotech Inc
Exchange NASDAQ | Headquaters Houston, TX, United States | ||
IPO Launch date 2016-06-02 | Co-Founder, Chairman, President & CEO Mr. Walter V. Klemp | ||
Sector Healthcare | Industry Biotechnology | Full time employees 17 | Website https://moleculin.com |
Full time employees 17 | Website https://moleculin.com | ||
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activator of transcription for brain tumors and pancreatic and other cancers. In addition, it is developing WP1122 portfolio, such as WP1122, WP1096, and WP1097 designed to exploit the uses of inhibitors of glycolysis comprising 2-deoxy-D-glucose for the treatment of pathogenic viruses and various cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.